Traws Pharma (ONTX) Revenue & Revenue Breakdown
Traws Pharma Revenue Highlights
Latest Revenue (Y)
$226.00B
Latest Revenue (Q)
$56.00K
Main Segment (Y)
Hanx Upfront Licence Payment
Main Geography (Y)
Hanx Upfront Licence Payment
Traws Pharma Revenue by Period
Traws Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $226.00B | 99999900.00% |
| 2022-12-31 | $226.00K | - |
| 2021-12-31 | $226.00K | -2.16% |
| 2020-12-31 | $231.00K | -89.42% |
| 2019-12-31 | $2.18M | 77.77% |
| 2018-12-31 | $1.23M | 56.04% |
| 2017-12-31 | $787.00K | -85.81% |
| 2016-12-31 | $5.55M | -51.59% |
| 2015-12-31 | $11.46M | 1332.00% |
| 2014-12-31 | $800.00K | -83.17% |
| 2013-12-31 | $4.75M | -89.71% |
| 2012-12-31 | $46.19M | 3006.25% |
| 2011-12-31 | $1.49M | - |
Traws Pharma generated $226.00B in revenue during NA 2023, up 99999900.00% compared to the previous quarter, and up 18403908.79% compared to the same period a year ago.
Traws Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $56.00K | - |
| 2023-12-31 | $56.00K | -1.75% |
| 2023-09-30 | $57.00K | - |
| 2023-06-30 | $57.00K | 1.79% |
| 2023-03-31 | $56.00K | - |
| 2022-12-31 | $56.00K | -1.75% |
| 2022-09-30 | $57.00K | - |
| 2022-06-30 | $57.00K | 1.79% |
| 2022-03-31 | $56.00K | - |
| 2021-12-31 | $56.00K | -1.75% |
| 2021-09-30 | $57.00K | - |
| 2021-06-30 | $57.00K | 1.79% |
| 2021-03-31 | $56.00K | -1.75% |
| 2020-12-31 | $57.00K | -13.64% |
| 2020-09-30 | $66.00K | 17.86% |
| 2020-06-30 | $56.00K | 7.69% |
| 2020-03-31 | $52.00K | 73.33% |
| 2019-12-31 | $30.00K | -52.38% |
| 2019-09-30 | $63.00K | -96.88% |
| 2019-06-30 | $2.02M | 2873.53% |
| 2019-03-31 | $68.00K | 15.25% |
| 2018-12-31 | $59.00K | -50.83% |
| 2018-09-30 | $120.00K | -75.26% |
| 2018-06-30 | $485.00K | -14.01% |
| 2018-03-31 | $564.00K | 294.41% |
| 2017-12-31 | $143.00K | 30.00% |
| 2017-09-30 | $110.00K | -66.05% |
| 2017-06-30 | $324.00K | 54.29% |
| 2017-03-31 | $210.00K | 21.39% |
| 2016-12-31 | $173.00K | -89.52% |
| 2016-09-30 | $1.65M | -26.56% |
| 2016-06-30 | $2.25M | 52.51% |
| 2016-03-31 | $1.47M | -84.64% |
| 2015-12-31 | $9.60M | 491.68% |
| 2015-09-30 | $1.62M | 1218.70% |
| 2015-06-30 | $123.00K | 7.89% |
| 2015-03-31 | $114.00K | - |
| 2014-12-31 | $114.00K | - |
| 2014-09-30 | $114.00K | -8.80% |
| 2014-06-30 | $125.00K | -72.04% |
| 2014-03-31 | $447.00K | -76.84% |
| 2013-12-31 | $1.93M | 72.94% |
| 2013-09-30 | $1.12M | 88.83% |
| 2013-06-30 | $591.00K | -47.04% |
| 2013-03-31 | $1.12M | -62.41% |
| 2012-12-31 | $2.97M | -93.06% |
| 2012-09-30 | $42.80M | 19355.91% |
| 2012-06-30 | $220.00K | 11.11% |
| 2012-03-31 | $198.00K | - |
Traws Pharma generated $56.00K in revenue during Q1 2024, up 0.00% compared to the previous quarter, and up 100.00% compared to the same period a year ago.
Traws Pharma Revenue Breakdown
Traws Pharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 18 |
|---|---|
| Pint Upfront Licence Payment | $319.00K |
| Supplies | $61.00K |
| Hanx Upfront Licence Payment | $450.00K |
| Symbio Amortization Of Upfront Payment | $398.00K |
Traws Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 18: Hanx Upfront Licence Payment (36.64%), Symbio Amortization Of Upfront Payment (32.41%), Pint Upfront Licence Payment (25.98%), and Supplies (4.97%).
Quarterly Revenue by Product
| Product/Service | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $57.00K | $57.00K | $56.00K | $56.00K | $56.00K | - | - | - | - | - | - |
| Supplies And Other | - | - | - | $10.00K | $-4.00K | - | - | - | - | - | - |
| Reimbursement Revenue | - | - | - | - | - | $6.00K | - | - | - | - | - |
| Rigosertib | - | - | - | - | - | $1.97M | - | - | - | - | - |
| Symbio Clinical Supplies | - | - | - | - | - | - | $1.00K | $11.00K | $6.00K | $53.00K | - |
| Symbio Amortization Of Upfront Payment | - | - | - | - | - | - | $56.00K | $57.00K | $114.00K | $113.00K | $114.00K |
| Hanx Upfront License Payment | - | - | - | - | - | - | $1.97M | - | - | - | - |
| Pint Upfront Licence Payment | - | - | - | - | - | - | - | - | - | $319.00K | - |
| Hanx Upfront Licence Payment | - | - | - | - | - | - | - | - | - | $450.00K | - |
Traws Pharma's latest quarterly revenue breakdown by segment (product or service), as of Sep 21: License (100.00%).
Traws Pharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 18 |
|---|---|
| Hanx Upfront Licence Payment | $450.00K |
| Symbio Amortization Of Upfront Payment | $398.00K |
| Pint Upfront Licence Payment | $319.00K |
| Supplies | $61.00K |
Traws Pharma's latest annual revenue breakdown by geography, as of Dec 18: Hanx Upfront Licence Payment (36.64%), Symbio Amortization Of Upfront Payment (32.41%), Pint Upfront Licence Payment (25.98%), and Supplies (4.97%).
Quarterly Revenue by Country
| Country | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $57.00K | $57.00K | $56.00K | $56.00K | $56.00K | - | - | - | - | - | - |
| Supplies And Other | - | - | - | $10.00K | $-4.00K | - | - | - | - | - | - |
| Reimbursement Revenue | - | - | - | - | - | $6.00K | - | - | - | - | - |
| Rigosertib | - | - | - | - | - | $1.97M | - | - | - | - | - |
| Hanx Upfront License Payment | - | - | - | - | - | - | $1.97M | - | - | - | - |
| Symbio Clinical Supplies | - | - | - | - | - | - | $1.00K | $11.00K | $6.00K | $53.00K | - |
| Symbio Amortization Of Upfront Payment | - | - | - | - | - | - | $56.00K | $57.00K | $114.00K | $113.00K | $114.00K |
| Pint Upfront Licence Payment | - | - | - | - | - | - | - | - | - | $319.00K | - |
| Hanx Upfront Licence Payment | - | - | - | - | - | - | - | - | - | $450.00K | - |
Traws Pharma's latest quarterly revenue breakdown by geography, as of Sep 21: License (100.00%).
Traws Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| JAGX | Jaguar Health | $9.76M | $2.72M |
| VBIV | VBI Vaccines | $8.68M | $1.21M |
| TNXP | Tonix Pharmaceuticals | $7.77M | $2.21M |
| VXRT | Vaxart | $7.38M | $6.40M |
| PULM | Pulmatrix | $7.30M | $1.55M |
| OCGN | Ocugen | $6.04M | $1.14M |
| AEZS | Aeterna Zentaris | $4.58M | $3.98K |
| CBIO | Gyre Therapeutics | $794.00K | - |
| PALI | Palisade Bio | $250.00K | - |
| SONN | Sonnet BioTherapeutics | $147.81K | - |
| BPTH | Bio-Path | - | - |
| MBRX | Moleculin Biotech | - | - |
| ADIL | Adial Pharmaceuticals | - | - |
| GOVX | GeoVax Labs | - | - |
| DFFN | CervoMed | - | - |
ONTX Revenue FAQ
What is Traws Pharma’s yearly revenue?
Traws Pharma's yearly revenue for 2023 was $226B, representing an increase of 99999900.00% compared to 2022. The company's yearly revenue for 2022 was $226K, representing an increase of 0% compared to 2021. ONTX's yearly revenue for 2021 was $226K, representing a decrease of -2.16% compared to 2020.
What is Traws Pharma’s quarterly revenue?
Traws Pharma's quarterly revenue for Q1 2024 was $56K, a 0% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $56K, a -1.75% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). ONTX's quarterly revenue for Q3 2023 was $57K, a 0% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Traws Pharma’s revenue growth rate?
Traws Pharma's revenue growth rate for the last 3 years (2021-2023) was 99999900.00%, and for the last 5 years (2019-2023) was 10352625.61%.
What are Traws Pharma’s revenue streams?
Traws Pharma's revenue streams in c 18 are Pint Upfront Licence Payment, Supplies, Hanx Upfront Licence Payment, and Symbio Amortization Of Upfront Payment. Pint Upfront Licence Payment generated $319K in revenue, accounting 25.98% of the company's total revenue Supplies generated $61K in revenue, accounting 4.97% of the company's total revenue Hanx Upfront Licence Payment generated $450K in revenue, accounting 36.64% of the company's total revenue Symbio Amortization Of Upfront Payment generated $398K in revenue, accounting 32.41% of the company's total revenue
What is Traws Pharma’s main source of revenue?
For the fiscal year ending Dec 18, the largest source of revenue of Traws Pharma was Hanx Upfront Licence Payment. This segment made a revenue of $450K, representing 36.64% of the company's total revenue.